GlassScriptPhysician profile
Kimberly Byrd
NPI 1710172119
$1,579.30
in general payments reported to CMS, 2019-2025
20 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $238 · 2022: $162 · 2023: $414 · 2024: $382 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $305.65 | 2023-2025 | Wegovy, Saxenda, Rybelsus |
| Lilly USA, LLC | $254.28 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $243.40 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $225.19 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $77.86 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $66.74 | 2021 | |
| Abbott Laboratories | $64.87 | 2024-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $53.94 | 2024-2025 | Airsupra, Farxiga |
| Neurocrine Biosciences, INC. | $40.54 | 2021-2022 | |
| Amgen INC. | $30.06 | 2025 | Otezla, Repatha |
| Seqirus USA INC | $27.86 | 2025 | Fluad, Flucelvax |
| Mylan Specialty L.P. | $25.94 | 2022 | |
| Insmed, INC. | $23.41 | 2023 | Arikayce |
| Exact Sciences Corporation | $22.03 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.42 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.75 | 2025 | Glassia |
| Harmony Biosciences LLC | $19.75 | 2025 | |
| Genzyme Corporation | $19.60 | 2024 | |
| Mallinckrodt Hospital Products INC. | $19.37 | 2023 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $17.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.